Other Information .
−Removed: During the three months ended March 31, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information.
+Added: During the three months ended June 30, 2026 , no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information.
The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q.
13 unchanged sentences
Sarepta Therapeutics, Inc.
+Added: 2026 Equity Incentive Plan
+Added: Sarepta Therapeutics, Inc.
+Added: 2026 Employee Stock Purchase Plan
+Added: Form of Stock Option Award Agreement under Sarepta Therapeutics, Inc.
+Added: 2026 Equity Incentive Plan
+Added: Form of Restricted Stock Unit Award Agreement under Sarepta Therapeutics, Inc.
+Added: 2026 Equity Incentive Plan
+Added: Employment Agreement, dated July 24, 2026, by and between Michael Severino, M.D., and Sarepta Therapeutics, Inc.
+Added: Consulting and Advisory Agreement, dated July 26, 2026, by and between Douglas Ingram and Sarepta Therapeutics, Inc.
+Added: Sarepta Therapeutics, Inc.
2024 Employment Commencement Incentive Plan
Amendment No.
−Removed: 1 to Sarepta Therapeutics, Inc.
+Added: 1 to the Sarepta Therapeutics, Inc.
2024 Employment Commencement Incentive Plan
−Removed: Sarepta Therapeutics, Inc.
−Removed: Non-Employee Director Compensation Policy
−Removed: Certification of the Company’s Principal Executive Officer, Douglas S.
−Removed: Ingram, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Amendment No.
+Added: 2 to the Sarepta Therapeutics, Inc.
+Added: 2024 Employment Commencement Incentive Plan
+Added: Amendment No.
+Added: 3 to the Sarepta Therapeutics, inc.
+Added: 2024 Employment Commencement Incentive Plan
+Added: Certification of the Company’s Principal Executive Officer, Michael Severino, M.D., pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of the Company’s Principal Financial and Accounting Officer, Ryan H.
Wong, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of the Company’s Principal Executive Officer, Douglas S.
−Removed: Ingram, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of the Company’s Principal Executive Officer, Michael Severino, M.D., pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Certification of the Company’s Principal Financial and Accounting Officer, Ryan H.
8 unchanged sentences
SAREPTA THERAPEUTICS, INC.
−Removed: /s/ DOUGLAS S.
+Added: August 5, 2026
+Added: /s/ MICHAEL SEVERINO, M.D.
+Added: Michael Severino, M.D.
Chief Executive Officer
(Principal Executive Officer)
+Added: August 5, 2026
Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.